ESSA PHARMA, INC. HAS BEGUN DEVELOPMENT OF A SECOND GENERATION ANITEN COMPOUND FOR THE TREATMENT OF HORMONE-DRIVEN CANCER

News

News Archives

Date Title

ESSA Pharma Inc. Becomes Reporting Issuer and Receives Conditional Approval to Commence Trading on TSX-V Exchange